Adoptive cell transfer as personalized immunotherapy for human cancer | Zendy

Steven A. Rosenberg | Zendy; Nicholas P. Restifo | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Adoptive cell transfer as personalized immunotherapy for human cancer

Author(s) -

Steven A. Rosenberg,

Nicholas P. Restifo

Publication year - 2015

Publication title -

science

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 12.556

H-Index - 1186

eISSN - 1095-9203

pISSN - 0036-8075

DOI - 10.1126/science.aaa4967

Subject(s) - adoptive cell transfer , cancer , chimeric antigen receptor , cancer immunotherapy , immunotherapy , melanoma , cancer research , somatic cell , immune system , immunology , cancer cell , receptor , cell therapy , antigen , medicine , cell , biology , t cell , genetics , gene

Adoptive cell therapy (ACT) is a highly personalized cancer therapy that involves administration to the cancer-bearing host of immune cells with direct anticancer activity. ACT using naturally occurring tumor-reactive lymphocytes has mediated durable, complete regressions in patients with melanoma, probably by targeting somatic mutations exclusive to each cancer. These results have expanded the reach of ACT to the treatment of common epithelial cancers. In addition, the ability to genetically engineer lymphocytes to express conventional T cell receptors or chimeric antigen receptors has further extended the successful application of ACT for cancer treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research